Home > News > Calando to Jointly Develop RNAi Therapeutics
February 3rd, 2006
Calando to Jointly Develop RNAi Therapeutics
Abstract:
Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its majority-owned subsidiary Calando Pharmaceuticals, Inc. and the National Cancer Institute (NCI) have established a collaborative development program to develop RNA interference (RNAi) therapeutics to fight a form of childhood cancer. Calando's self-assembling RNAi therapeutic nanoparticle contains linear cyclodextrin (a form of sugar), an siRNA and a targeting molecule.
Source:
businesswire
Bookmark:
Possible Futures
Space Solar Power: Key to a Livable Planet Earth June 10th, 2013
Global Nanotechnology Drug Delivery Market 2012-2016 June 10th, 2013
Nanorobot tetanus treatment animation June 9th, 2013
New horizons to drive the future of Medicine: European Technology Platform on Nanomedicine intends to lead the domain June 8th, 2013
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Materials
Working backward: Computer-aided design of zeolite templates: Rice scientists apply drug-design lessons to production of industrial minerals June 17th, 2013
Discover the ‘Nanostructure Advantage’ at ECerS 2013, Booth 5: Innovnano presents nanostructured powders for high performance ceramics June 17th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
Ceramics in Paper Manufacturing including Advanced and Nano Materials: Author- Dr. Mahendra Patel, 420 pages; 32 chapters, Publ.2013 June 12th, 2013
Announcements
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013